Literature DB >> 14979606

Bioequivalence study of two formulations of simvastatin tablets in healthy Thai volunteers.

Manupat Lohitnavy1, Ornrat Lohitnavy, Kasinee Chaijittiprasert, Prawit Taytiwat, Sanglar Polnok.   

Abstract

The bioequivalence of two formulations of 10 mg tablets of simvastatin (CAS 79902-63-9), Vascor as test and a commercially available preparation as reference, in 18 healthy Thai male volunteers was assessed. In a randomized, single dose, two-period, crossover study design with a 1-week wash-out period, each subject received 4 tablets of 10-mg simvastatin tablets. Plasma samples were collected over a 24-h period after administration. Subsequently, plasma concentrations of simvastatin and its hydroxy acid metabolite were analyzed by using LC/ MS/MS. Pharmacokinetic parameters were determined by using non-compartmental analysis. The results showed that 90% confidence intervals of the peak concentration (Cmax) and the area under the concentration-time curve (AUC) of simvastatin and its hydroxy acid metabolite of reference and test were within 80 %-125%. Consequently the bioequivalence of these two preparations can be concluded.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14979606     DOI: 10.1055/s-0031-1296933

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

1.  Single-dose bioequivalence assessment of two formulations of polysaccharide iron complex capsules in healthy adult male Chinese volunteers: A sequence-randomized, double-blind, two-way crossover study.

Authors:  Yuan-Yuan Zhang; Jun-Hong Liu; Feng Su; Ying-Tao Lui; Jun-Feng Li
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

2.  Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

Authors:  Rosie Z Yu; Richard S Geary; Joann D Flaim; Gina C Riley; Diane L Tribble; André A vanVliet; Mark K Wedel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.